Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
This study has been terminated.
( Poor trial recruitment )
Study NCT00753740   Information provided by Calando Pharmaceuticals
First Received: September 12, 2008   Last Updated: June 3, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Ovarian Cancer
Solid Tumor
Additional conditions recognized in this trial
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Interventions listed in this trial
IT-101 (12mg/m2/dose)
IT-101 (15mg/m2/dose)
5% Dextrose (Placebo)
Sponsors listed in this trial
Calando Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services